BR112012029986A2 - - Google Patents
Info
- Publication number
- BR112012029986A2 BR112012029986A2 BR112012029986A BR112012029986A BR112012029986A2 BR 112012029986 A2 BR112012029986 A2 BR 112012029986A2 BR 112012029986 A BR112012029986 A BR 112012029986A BR 112012029986 A BR112012029986 A BR 112012029986A BR 112012029986 A2 BR112012029986 A2 BR 112012029986A2
- Authority
- BR
- Brazil
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/22—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against growth factors ; against growth regulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/18—Growth factors; Growth regulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
- A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
- A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
- A61K47/42—Proteins; Polypeptides; Degradation products thereof; Derivatives thereof, e.g. albumin, gelatin or zein
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K49/00—Preparations for testing in vivo
- A61K49/06—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations
- A61K49/08—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations characterised by the carrier
- A61K49/10—Organic compounds
- A61K49/14—Peptides, e.g. proteins
- A61K49/16—Antibodies; Immunoglobulins; Fragments thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
- A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
- A61P21/04—Drugs for disorders of the muscular or neuromuscular system for myasthenia gravis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
- A61P21/06—Anabolic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/475—Growth factors; Growth regulators
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
- C07K2317/565—Complementarity determining region [CDR]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
- C07K2317/567—Framework region [FR]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/94—Stability, e.g. half-life, pH, temperature or enzyme-resistance
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Organic Chemistry (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Immunology (AREA)
- Engineering & Computer Science (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Molecular Biology (AREA)
- Genetics & Genomics (AREA)
- Epidemiology (AREA)
- Biochemistry (AREA)
- Biophysics (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Physical Education & Sports Medicine (AREA)
- General Chemical & Material Sciences (AREA)
- Gastroenterology & Hepatology (AREA)
- Zoology (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Rheumatology (AREA)
- Toxicology (AREA)
- Mycology (AREA)
- Microbiology (AREA)
- Neurology (AREA)
- Endocrinology (AREA)
- Diabetes (AREA)
- Radiology & Medical Imaging (AREA)
- Hematology (AREA)
- Biotechnology (AREA)
- Inorganic Chemistry (AREA)
- Obesity (AREA)
- Peptides Or Proteins (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
Applications Claiming Priority (5)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US34855910P | 2010-05-26 | 2010-05-26 | |
US61/348,559 | 2010-05-26 | ||
US37288210P | 2010-08-12 | 2010-08-12 | |
US61/372,882 | 2010-08-12 | ||
PCT/US2011/037837 WO2011150008A1 (en) | 2010-05-26 | 2011-05-25 | Antibodies to human gdf8 |
Publications (2)
Publication Number | Publication Date |
---|---|
BR112012029986A2 true BR112012029986A2 (US07935481-20110503-C00024.png) | 2017-08-22 |
BR112012029986B1 BR112012029986B1 (pt) | 2022-05-24 |
Family
ID=44477626
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
BR112012029986-7A BR112012029986B1 (pt) | 2010-05-26 | 2011-05-25 | Anticorpo humano isolado ou fragmento de ligação ao antígeno do mesmo que se liga especificamente ou bloqueia a atividade biológica de gdf8 humano maduro do tipo selvagem, composição farmacêutica e usos dos mesmos |
Country Status (40)
Families Citing this family (69)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
ES2568436T3 (es) | 2006-03-31 | 2016-04-29 | Chugai Seiyaku Kabushiki Kaisha | Procedimiento para controlar la farmacocinética en sangre de anticuerpos |
CN106519025B (zh) | 2007-09-26 | 2021-04-23 | 中外制药株式会社 | 利用cdr的氨基酸取代来改变抗体等电点的方法 |
PL2708558T3 (pl) | 2008-04-11 | 2018-09-28 | Chugai Seiyaku Kabushiki Kaisha | Cząsteczka wiążąca antygen zdolna do wiązania dwóch lub więcej cząsteczek antygenu w sposób powtarzalny |
JO3340B1 (ar) | 2010-05-26 | 2019-03-13 | Regeneron Pharma | مضادات حيوية لـعامل تمايز النمو 8 البشري |
NZ608206A (en) | 2010-08-16 | 2015-02-27 | Amgen Inc | Antibodies that bind myostatin, compositions and methods |
SG10201509790YA (en) | 2010-11-30 | 2015-12-30 | Chugai Pharmaceutical Co Ltd | Antigen-Binding Molecule Capable Of Binding To Plurality Of Antigen Molecules Repeatedly |
KR102048189B1 (ko) | 2011-11-14 | 2019-11-25 | 리제너론 파아마슈티컬스, 인크. | Gdf8 및/또는 액티빈 a를 특이적으로 길항함으로써 근육량과 근육 강도를 증가시키는 조성물 및 방법 |
JO3820B1 (ar) | 2012-05-03 | 2021-01-31 | Regeneron Pharma | أجسام مضادة بشرية لـ fel d1وطرق لاستخدامها |
TWI641687B (zh) * | 2012-05-29 | 2018-11-21 | 美商再生元醫藥公司 | 生產細胞株增強子 |
TW202340236A (zh) | 2012-08-24 | 2023-10-16 | 日商中外製藥股份有限公司 | FcγRIIb特異性Fc區域變異體 |
EP3597747B1 (en) | 2012-08-24 | 2023-03-15 | Chugai Seiyaku Kabushiki Kaisha | Mouse fcgammarii-specific fc antibody |
US8933199B2 (en) | 2012-09-13 | 2015-01-13 | Bristol-Myers Squibb Company | Fibronectin based scaffold domain proteins that bind to myostatin |
CN104981250A (zh) | 2012-10-24 | 2015-10-14 | 细胞基因公司 | 用于治疗贫血的方法 |
AR095196A1 (es) | 2013-03-15 | 2015-09-30 | Regeneron Pharma | Medio de cultivo celular libre de suero |
EP2968503B1 (en) | 2013-03-15 | 2018-08-15 | Intrinsic LifeSciences LLC | Anti-hepcidin antibodies and uses thereof |
JP6598680B2 (ja) | 2013-04-02 | 2019-10-30 | 中外製薬株式会社 | Fc領域改変体 |
SG10201913751RA (en) | 2013-05-06 | 2020-03-30 | Scholar Rock Inc | Compositions and methods for growth factor modulation |
TW201920262A (zh) * | 2013-07-30 | 2019-06-01 | 美商再生元醫藥公司 | 抗活化素a之抗體及其用途 |
EP3564671B1 (en) | 2013-08-23 | 2021-09-29 | Regeneron Pharmaceuticals, Inc. | Diagnostic tests and methods for assessing safety, efficacy or outcome of allergen-specific immunotherapy (sit) |
EP3197915A4 (en) | 2014-09-22 | 2018-12-19 | Intrinsic Lifesciences LLC | Humanized anti-hepcidin antibodies and uses thereof |
CA3005158A1 (en) | 2014-11-06 | 2016-05-12 | Scholar Rock, Inc. | Anti-pro/latent-myostatin antibodies and uses thereof |
JP6768651B2 (ja) | 2014-11-24 | 2020-10-14 | ソマロジック, インコーポレイテッドSomaLogic, Inc. | 増殖分化因子11と結合するための核酸化合物 |
BR112017006736A2 (pt) | 2014-12-19 | 2017-12-19 | Chugai Pharmaceutical Co Ltd | anticorpos antimiostatina, polipeptídeos contendo regiões fc variantes, e métodos de utilização |
SG11201706014PA (en) | 2015-02-05 | 2017-08-30 | Chugai Pharmaceutical Co Ltd | Antibodies comprising an ion concentration dependent antigen-binding domain, fc region variants, il-8-binding antibodies, and uses therof |
US20180031579A1 (en) | 2015-02-12 | 2018-02-01 | INSERM (Institut National de la Santé et de la Recherche Médicale) | Methods for predicting the responsiveness of a patient affected with malignant hematological disease to chemotherapy treatment and methods of treatment of such disease |
CN107771081A (zh) * | 2015-04-15 | 2018-03-06 | 瑞泽恩制药公司 | 用gdf8抑制剂增加力量和功能的方法 |
TW202330904A (zh) | 2015-08-04 | 2023-08-01 | 美商再生元醫藥公司 | 補充牛磺酸之細胞培養基及用法 |
LT3350220T (lt) | 2015-09-15 | 2021-09-27 | Scholar Rock, Inc. | Anti pro/latentinio miostatino antikūnai ir jų panaudojimas |
JP7141336B2 (ja) | 2015-12-25 | 2022-09-22 | 中外製薬株式会社 | 抗ミオスタチン抗体および使用方法 |
MX2018008369A (es) | 2016-01-08 | 2019-05-15 | Scholar Rock Inc | Anticuerpos de anti-miostatina pro/latente y metodo de uso de los mismos. |
RS61090B1 (sr) | 2016-06-13 | 2020-12-31 | Scholar Rock Inc | Upotreba inhibitora miostatina i kombinovane terapije |
CA3026050A1 (en) | 2016-08-05 | 2018-02-08 | Chugai Seiyaku Kabushiki Kaisha | Composition for prophylaxis or treatment of il-8 related diseases |
EP3504328A1 (en) | 2016-08-24 | 2019-07-03 | Regeneron Pharmaceuticals, Inc. | Host cell protein modification |
CN106770517A (zh) * | 2016-12-16 | 2017-05-31 | 青岛科技大学 | 一种检测力竭运动后小鼠骨骼肌肌肉生长抑制素含量的方法 |
EP3558347A1 (en) | 2016-12-22 | 2019-10-30 | Regeneron Pharmaceuticals, Inc. | Method of treating an allergy with allergen-specific monoclonal antibodies |
FI3565592T3 (fi) | 2017-01-06 | 2023-05-10 | Scholar Rock Inc | Metabolisten tautien hoitaminen estämällä myostatiinin aktivaatio |
CN110914293A (zh) | 2017-07-06 | 2020-03-24 | 里珍纳龙药品有限公司 | 用于制备糖蛋白的细胞培养工艺 |
KR20200103728A (ko) | 2017-12-22 | 2020-09-02 | 리제너론 파마슈티칼스 인코포레이티드 | 약물 제품 불순물 특성화를 위한 시스템 및 방법 |
WO2019129679A1 (en) * | 2017-12-29 | 2019-07-04 | F. Hoffmann-La Roche Ag | Method for improving vegf-receptor blocking selectivity of an anti-vegf antibody |
EA202091689A1 (ru) | 2018-01-31 | 2020-10-22 | Ридженерон Фармасьютикалз, Инк. | Система и способ определения характеристик примесей, представляющих собой варианты, отличающиеся по размеру и заряду, в продукте, представляющем собой лекарственное средство |
TW202311746A (zh) | 2018-02-02 | 2023-03-16 | 美商再生元醫藥公司 | 用於表徵蛋白質二聚合之系統及方法 |
CA3088906A1 (en) | 2018-02-28 | 2019-09-06 | Regeneron Pharmaceuticals, Inc. | Systems and methods for identifying viral contaminants |
US11248044B2 (en) | 2018-03-01 | 2022-02-15 | Regeneron Pharmaceuticals, Inc. | Methods for altering body composition by administering a GDF8 inhibitor and an Activin A inhibitor |
EA202092203A1 (ru) | 2018-03-19 | 2020-12-07 | Ридженерон Фармасьютикалз, Инк. | Способы анализа и реагенты для микрочипового капиллярного электрофореза |
TW202016125A (zh) | 2018-05-10 | 2020-05-01 | 美商再生元醫藥公司 | 用於定量及調節蛋白質黏度之系統與方法 |
JP2021535739A (ja) | 2018-08-27 | 2021-12-23 | リジェネロン・ファーマシューティカルズ・インコーポレイテッド | 下流精製でのラマン分光法の使用 |
AU2019333047A1 (en) | 2018-08-30 | 2020-12-03 | Regeneron Pharmaceuticals, Inc. | Methods for characterizing protein complexes |
JP2022512346A (ja) * | 2018-12-18 | 2022-02-03 | リジェネロン・ファーマシューティカルズ・インコーポレイテッド | レプチン受容体、gdf8、およびアクチビンaに対するアンタゴニストを使用して、体重および除脂肪筋肉量を増やすための組成物および方法 |
EP4220173A3 (en) | 2019-01-16 | 2023-10-18 | Regeneron Pharmaceuticals, Inc. | Methods for characterizing disulfide bonds |
CA3135004A1 (en) | 2019-05-13 | 2020-11-19 | Regeneron Pharmaceuticals, Inc. | Improved competitive ligand binding assays |
AU2020352547A1 (en) | 2019-09-24 | 2022-03-31 | Regeneron Pharmaceuticals, Inc. | Systems and methods for chromatography use and regeneration |
BR112022009974A2 (pt) | 2019-11-25 | 2022-08-16 | Regeneron Pharma | Métodos de produção de um polímero ou micropartículas revestidas com polímero, para produzir microesferas poliméricas ou revestidas com polímero e para produzir micropartículas, composição de liberação sustentada, micropartículas, e, composição farmacêutica |
WO2021142331A1 (en) * | 2020-01-10 | 2021-07-15 | Dyne Therapeutics, Inc. | Muscle targeting complexes and uses thereof for modulation of genes associated with cardiac muscle disease |
WO2021142269A1 (en) * | 2020-01-10 | 2021-07-15 | Dyne Therapeutics, Inc. | Muscle targeting complexes and uses thereof for modulation of genes associated with muscle atrophy |
US11835527B2 (en) | 2020-01-21 | 2023-12-05 | Regeneron Pharmaceuticals, Inc. | Deglycosylation methods for electrophoresis of glycosylated proteins |
MX2023002417A (es) | 2020-08-31 | 2023-03-22 | Regeneron Pharma | Estrategias de suministro de asparagina para mejorar el rendimiento del cultivo celular y mitigar las variantes de secuencia de asparagina. |
MX2023006077A (es) | 2020-11-25 | 2023-06-06 | Regeneron Pharma | Formulaciones de liberacion sostenida mediante emulsificacion por membrana no acuosa. |
EP4262757A1 (en) | 2020-12-17 | 2023-10-25 | Regeneron Pharmaceuticals, Inc. | Fabrication of protein-encapsulating microgels |
US20220228107A1 (en) | 2021-01-20 | 2022-07-21 | Regeneron Pharmaceuticals, Inc. | Methods of improving protein titer in cell culture |
WO2022187323A1 (en) | 2021-03-03 | 2022-09-09 | Regeneron Pharmaceuticals, Inc. | Systems and methods for quantifying and modifying protein viscosity |
MX2023010794A (es) | 2021-03-26 | 2023-10-25 | Regeneron Pharma | Metodos y sistemas para el desarrollo de protocolos de mezcla. |
KR20240015646A (ko) | 2021-06-01 | 2024-02-05 | 리제너론 파마슈티칼스 인코포레이티드 | 마이크로칩 모세관 전기영동 분석 및 시약 |
TW202326138A (zh) | 2021-09-08 | 2023-07-01 | 美商再生元醫藥公司 | 用於定量抗體及其他含Fc蛋白之高通量及基於質譜之方法 |
IL311527A (en) | 2021-09-20 | 2024-05-01 | Regeneron Pharma | Methods for controlling antibody heterogeneity |
TW202331252A (zh) | 2021-10-07 | 2023-08-01 | 美商再生元醫藥公司 | Ph計校準與校正 |
US20230116199A1 (en) | 2021-10-07 | 2023-04-13 | Regeneron Pharmaceuticals, Inc. | Systems and methods of ph modeling and control |
CN118176167A (zh) | 2021-10-26 | 2024-06-11 | 瑞泽恩制药公司 | 用于产生实验室用水和分配处于不同温度的实验室用水的系统和方法 |
TW202346856A (zh) | 2022-03-18 | 2023-12-01 | 美商里珍納龍藥品有限公司 | 分析多肽變體的方法及系統 |
WO2024064842A1 (en) | 2022-09-21 | 2024-03-28 | Regeneron Pharmaceuticals, Inc. | Methods of treating obesity, diabetes, and liver dysfunction |
Family Cites Families (38)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
IL85035A0 (en) | 1987-01-08 | 1988-06-30 | Int Genetic Eng | Polynucleotide molecule,a chimeric antibody with specificity for human b cell surface antigen,a process for the preparation and methods utilizing the same |
JP4124480B2 (ja) | 1991-06-14 | 2008-07-23 | ジェネンテック・インコーポレーテッド | 免疫グロブリン変異体 |
US5994618A (en) | 1997-02-05 | 1999-11-30 | Johns Hopkins University School Of Medicine | Growth differentiation factor-8 transgenic mice |
DE69432815T2 (de) | 1993-03-19 | 2003-12-11 | Univ Johns Hopkins Med | Wachstumsfaktor-8 |
EP1075272B1 (en) | 1998-05-06 | 2009-07-15 | Metamorphix, Inc. | Methods for treating diabetes by inhibiting gdf-8 |
MXPA01013232A (es) | 1999-07-20 | 2005-05-24 | Pharmexa As | Metodo para identificar la actividad de gdf-8. |
US7320789B2 (en) | 2001-09-26 | 2008-01-22 | Wyeth | Antibody inhibitors of GDF-8 and uses thereof |
AR047392A1 (es) | 2002-10-22 | 2006-01-18 | Wyeth Corp | Neutralizacion de anticuerpos contra gdf 8 y su uso para tales fines |
US20040101920A1 (en) | 2002-11-01 | 2004-05-27 | Czeslaw Radziejewski | Modification assisted profiling (MAP) methodology |
SI1581649T1 (sl) * | 2002-12-20 | 2011-09-30 | Amgen Inc | Vezna sredstva, ki zavirajo miostatin |
JP5110877B2 (ja) | 2003-06-02 | 2012-12-26 | ワイス・エルエルシー | 神経筋障害を処置するための、コルチコステロイドと組み合わせたミオスタチン(gdf8)インヒビターの使用 |
JP2007535912A (ja) | 2003-12-31 | 2007-12-13 | シェーリング−プラウ・リミテッド | 中和エピトープベースの増殖増強性ワクチン |
US7456149B2 (en) | 2004-03-02 | 2008-11-25 | Acceleron Pharma, Inc. | ALK7 and myostatin inhibitors and uses thereof |
US20070178095A1 (en) | 2004-03-23 | 2007-08-02 | Eli Lilly And Company | Anti-myostatin antibodies |
US7850962B2 (en) | 2004-04-20 | 2010-12-14 | Genmab A/S | Human monoclonal antibodies against CD20 |
CN101001642A (zh) | 2004-08-12 | 2007-07-18 | 惠氏公司 | 使用gdf-8抑制剂对糖尿病、肥胖症和心血管病的联合治疗 |
NZ538097A (en) | 2005-02-07 | 2006-07-28 | Ovita Ltd | Method and compositions for improving wound healing |
CN101272802A (zh) | 2005-04-25 | 2008-09-24 | 辉瑞大药厂 | 肌肉生长抑制素的抗体 |
WO2007024535A2 (en) | 2005-08-19 | 2007-03-01 | Wyeth | Antagonist antibodies against gdf-8 and uses in treatment of als and other gdf-8-associated disorders |
CA2624976A1 (en) | 2005-10-06 | 2007-04-19 | Eli Lilly And Company | Anti-myostatin antibodies |
UA92504C2 (en) | 2005-10-12 | 2010-11-10 | Эли Лилли Энд Компани | Anti-myostatin monoclonal antibody |
WO2007067616A2 (en) | 2005-12-06 | 2007-06-14 | Amgen Inc | Uses of myostatin antagonists |
US7699146B1 (en) | 2006-04-02 | 2010-04-20 | Fox Factory, Inc. | Suspension damper having inertia valve and user adjustable pressure-relief |
PT2374818E (pt) | 2006-06-02 | 2013-02-13 | Regeneron Pharma | Anticorpos com elevada afinidade para o receptor il-6 humano |
WO2008016314A1 (en) * | 2006-08-03 | 2008-02-07 | Orico Limited | Myostatin antagonists |
EA015916B1 (ru) | 2006-09-05 | 2011-12-30 | Эли Лилли Энд Компани | Моноклональные антитела к миостатину и их применения |
CL2007002567A1 (es) | 2006-09-08 | 2008-02-01 | Amgen Inc | Proteinas aisladas de enlace a activina a humana. |
CN100586476C (zh) * | 2006-10-13 | 2010-02-03 | 中国人民解放军第四军医大学 | 一种Myostatin特异性抗体的治疗性疫苗及其制备方法 |
TW201718635A (zh) | 2007-03-06 | 2017-06-01 | 安美基公司 | 變異之活動素受體多肽及其用途 |
PE20091163A1 (es) * | 2007-11-01 | 2009-08-09 | Wyeth Corp | Anticuerpos para gdf8 |
PL2207775T3 (pl) | 2007-11-05 | 2012-08-31 | Novartis Ag | Pochodne 4-benzyloamino-1-karboksyacylo-piperydyny jako inhibitory CETP użyteczne do leczenia chorób, takich jak hiperlipidemia lub stwardnienie tętnic |
FI3750552T3 (fi) | 2008-08-14 | 2023-07-25 | Acceleron Pharma Inc | Gdf-loukkuja |
TW201029662A (en) * | 2008-12-19 | 2010-08-16 | Glaxo Group Ltd | Novel antigen binding proteins |
PT2424895T (pt) | 2009-04-27 | 2017-12-15 | Novartis Ag | Composições e métodos para aumentar o crescimento muscular |
CN103833855A (zh) | 2009-06-26 | 2014-06-04 | 瑞泽恩制药公司 | 容易地分离的具有天然免疫球蛋白形式的双特异性抗体 |
JO3340B1 (ar) | 2010-05-26 | 2019-03-13 | Regeneron Pharma | مضادات حيوية لـعامل تمايز النمو 8 البشري |
KR102048189B1 (ko) | 2011-11-14 | 2019-11-25 | 리제너론 파아마슈티컬스, 인크. | Gdf8 및/또는 액티빈 a를 특이적으로 길항함으로써 근육량과 근육 강도를 증가시키는 조성물 및 방법 |
TW201920262A (zh) | 2013-07-30 | 2019-06-01 | 美商再生元醫藥公司 | 抗活化素a之抗體及其用途 |
-
2011
- 2011-05-17 JO JOP/2011/0164A patent/JO3340B1/ar active
- 2011-05-24 AR ARP110101772A patent/AR081221A1/es active IP Right Grant
- 2011-05-25 EP EP11726005.9A patent/EP2576618B1/en active Active
- 2011-05-25 ES ES11726005.9T patent/ES2647389T3/es active Active
- 2011-05-25 SG SG2012081964A patent/SG185455A1/en unknown
- 2011-05-25 LT LTEP11726005.9T patent/LT2576618T/lt unknown
- 2011-05-25 CA CA2800581A patent/CA2800581C/en active Active
- 2011-05-25 WO PCT/US2011/037837 patent/WO2011150008A1/en active Application Filing
- 2011-05-25 SG SG10201504092TA patent/SG10201504092TA/en unknown
- 2011-05-25 RU RU2012156938/10A patent/RU2567805C2/ru active
- 2011-05-25 TW TW100118221A patent/TWI602917B/zh active
- 2011-05-25 MY MYPI2012004862A patent/MY157109A/en unknown
- 2011-05-25 BR BR112012029986-7A patent/BR112012029986B1/pt active IP Right Grant
- 2011-05-25 HU HUE11726005A patent/HUE037140T2/hu unknown
- 2011-05-25 PT PT117260059T patent/PT2576618T/pt unknown
- 2011-05-25 UY UY0001033407A patent/UY33407A/es unknown
- 2011-05-25 PE PE2012002209A patent/PE20130226A1/es active IP Right Grant
- 2011-05-25 RU RU2015143242A patent/RU2710156C2/ru active
- 2011-05-25 MX MX2015005551A patent/MX357145B/es unknown
- 2011-05-25 DK DK11726005.9T patent/DK2576618T3/en active
- 2011-05-25 AU AU2011258342A patent/AU2011258342B2/en active Active
- 2011-05-25 NZ NZ603529A patent/NZ603529A/en unknown
- 2011-05-25 SI SI201131297T patent/SI2576618T1/sl unknown
- 2011-05-25 RS RS20170931A patent/RS56368B1/sr unknown
- 2011-05-25 NO NO11726005A patent/NO2576618T3/no unknown
- 2011-05-25 TW TW105109351A patent/TW201701903A/zh unknown
- 2011-05-25 MX MX2012013369A patent/MX2012013369A/es active IP Right Grant
- 2011-05-25 US US13/115,170 patent/US8840894B2/en active Active
- 2011-05-25 CN CN201180025908.2A patent/CN102933602B/zh active Active
- 2011-05-25 JP JP2013512186A patent/JP5896993B2/ja active Active
- 2011-05-25 KR KR1020127033587A patent/KR101859911B1/ko active IP Right Grant
- 2011-05-25 PL PL11726005T patent/PL2576618T3/pl unknown
-
2012
- 2012-11-12 IL IL223003A patent/IL223003A/en active IP Right Grant
- 2012-11-13 CR CR20120577A patent/CR20120577A/es unknown
- 2012-11-13 ZA ZA2012/08525A patent/ZA201208525B/en unknown
- 2012-11-14 NI NI201200171A patent/NI201200171A/es unknown
- 2012-11-20 DO DO2012000295A patent/DOP2012000295A/es unknown
- 2012-11-23 GT GT201200318A patent/GT201200318A/es unknown
- 2012-11-23 TN TNP2012000555A patent/TN2012000555A1/en unknown
- 2012-11-23 CL CL2012003283A patent/CL2012003283A1/es unknown
- 2012-11-26 EC ECSP12012309 patent/ECSP12012309A/es unknown
- 2012-12-26 CO CO12233131A patent/CO6620013A2/es unknown
-
2014
- 2014-08-18 US US14/462,085 patent/US9260515B2/en active Active
-
2015
- 2015-12-18 US US14/974,147 patent/US9890212B2/en active Active
-
2017
- 2017-10-05 HR HRP20171499TT patent/HRP20171499T1/hr unknown
- 2017-10-11 CY CY20171101065T patent/CY1119445T1/el unknown
-
2018
- 2018-01-02 US US15/860,200 patent/US20190023777A1/en not_active Abandoned
-
2022
- 2022-10-11 US US18/045,588 patent/US20240067712A1/en active Pending
Also Published As
Similar Documents
Legal Events
Date | Code | Title | Description |
---|---|---|---|
B07D | Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette] | ||
B06F | Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette] | ||
B07E | Notification of approval relating to section 229 industrial property law [chapter 7.5 patent gazette] |
Free format text: NOTIFICACAO DE ANUENCIA RELACIONADA COM O ART 229 DA LPI |
|
B06T | Formal requirements before examination [chapter 6.20 patent gazette] | ||
B06A | Patent application procedure suspended [chapter 6.1 patent gazette] | ||
B09A | Decision: intention to grant [chapter 9.1 patent gazette] | ||
B16A | Patent or certificate of addition of invention granted [chapter 16.1 patent gazette] |
Free format text: PRAZO DE VALIDADE: 20 (VINTE) ANOS CONTADOS A PARTIR DE 25/05/2011, OBSERVADAS AS CONDICOES LEGAIS. PATENTE CONCEDIDA CONFORME ADI 5.529/DF, QUE DETERMINA A ALTERACAO DO PRAZO DE CONCESSAO. |